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Although there are many prospective targets in the
tumor microenvironment (TME) of high-grade serous
ovarian cancer (HGSOC), pre-clinical testing is chal-
lenging, especially as there is limited information
on the murine TME. Here, we characterize the TME
of six orthotopic, transplantable syngeneic murine
HGSOC lines established from genetic models and
compare these to patient biopsies.We identify signif-
icant correlations between the transcriptome, host
cell infiltrates, matrisome, vasculature, and tissue
modulus of mouse and human TMEs, with several
stromal and malignant targets in common. However,
each model shows distinct differences and potential
vulnerabilities that enabled us to test predictions
about response to chemotherapy and an anti-IL-6
antibody. Using machine learning, the transcriptional
profiles of the mouse tumors that differed in chemo-
therapy response are able to classify chemo-
therapy-sensitive and -refractory patient tumors.
These models provide useful pre-clinical tools and
may help identify subgroups of HGSOC patients
who are most likely to respond to specific therapies.
INTRODUCTION
Human tumors comprise a complex mixture of malignant cells,
immune, and other stromal cells regulated by a dynamic network
of soluble mediators and adhesion molecules. All of these com-
ponents interact in an abnormal extracellular matrix (ECM), often
referred to as the tumor matrisome (Socovich and Naba, 2018).Cell
This is an open access article undNot only is this tumor microenvironment (TME) critical for the
growth and spread of human cancers but also the non-malignant
components are important targets for immunological and other
biological therapies (Binnewies et al., 2018; Foster et al., 2018;
Mantovani et al., 2017).
We recently conducted multi-layered TME profiling of evolving
omental metastases of human high-grade serous ovarian cancer
(HGSOC), describing gene and protein profiles that are associ-
ated with tissue stiffness, extent of disease, and cellularity
(Pearce et al., 2018). During this analysis, we defined a 22-
gene matrisome signature, the Matrix Index, which predicted
the extent of disease, tissue remodeling, and tissue stiffness.
When we interrogated publicly available transcriptional datasets
from >9,000 primary tumor biopsies, we found that a high Matrix
Index distinguished patients with shorter overall survival, not
only in ovarian cancer but also in 12 other human cancer types.
This suggested that there may be a common host matrix
response in human primary and metastatic cancers (Pearce
et al., 2018). As regulators of these matrisome molecules may
be important therapeutic targets across many different cancer
types, pre-clinical models that replicate the malignant matri-
some and immune landscapes are of critical importance.
However, it is not clearwhether TMEs ofmurine cancermodels
sufficiently replicate their human counterparts. Differences be-
tween the human andmouse TMEsmay compromise pre-clinical
studies of novel immune and other biological therapies and their
successful translation to clinical trials. Many murine cancer
models may not have appropriate oncogenic mutations and
may be grown in immunocompromised animals or in unsuitable
anatomical sites; others grow too rapidly for a TME to develop
fully or too slowly for pre-clinical studies to be feasible.
HGSOC is typified by ubiquitous TP53 mutations/deletions
(Ahmed et al., 2010; The Cancer Genome Atlas Research
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BRCA1 or -2 alterations are found. The phosphatidylinositol
3-kinase (PI3K) pathways, through phophatase and tensin
homolog (PTEN) deletion and othermechanisms, and retinoblas-
toma (RB) pathways are also often altered (The Cancer Genome
Atlas Research Network, 2011). Most other mutations are of low
frequency, but copy number alterations (CNAs) are frequent and
complex (Macintyre et al., 2018). Previous mouse models of
HGSOC include peritoneal xenografts from human cell lines of
uncertain origin or syngeneic transplantable models such as
ID8 that do not possess appropriate mutations. Genetic engi-
neering of the ID8 model by CRISPR/Cas9 has resulted in a
more suitable transplantable model with Trp53 and Brca2 dele-
tions (Walton et al., 2016). There are several useful genetically
engineered mouse models (GEMMs) of HGSOC (Perets et al.,
2013; Zhai et al., 2017), but their mixed backgrounds and
complex breeding programs make them unsuitable for studies
of tumor immunity and immunotherapy (Stuckelberger and
Drapkin, 2018).
To find models of the HGSOC TME that replicate the immune
and matrisome components of human disease, we studied a
range of murine models that have disease-relevant genetic
mutations, are transplantable, and are relatively slow growing.
We chose models that develop metastases in one of the most
common sites found in women, the omentum, a metastatic site
that we have extensively characterized in patient biopsies
(Bo¨hm et al., 2016; Montfort et al., 2017; Pearce et al., 2018).
Four of these models were generated in our laboratory from
tumors that developed in a GEMM (Perets et al., 2013) that we
backcrossed onto a B6 background, and two were cell lines
that had been originally established from tumors from GEMM
tumors generated by adenoviral transduction (Szabova et al.,
2014). We then conducted multi-level molecular and cellular
profiling of murine peritoneal metastases in these six different
transplantable mouse models to determine their suitability as
models for human HGSOC.
Here, we demonstrate that many of the biomechanical,
cellular, and molecular features of human HGSOC are replicated
in the murine tumors with significant correlations in mRNA
expression profiles, innate and adaptive immune responses,
tissue modulus, and matrisome components. Further high-
lighting the utility of these models as avatars of human disease,
we find that themousemodels exhibit significant differences and
distinct vulnerabilities in their TMEs, reflecting the heterogeneity
of human HGSOC biopsies. Using this model platform, we con-
ducted proof-of-concept studies that demonstrate the potential
of this repertoire of models for pre-clinical studies and found that
the transcriptional profile of chemotherapy-responsive murine
tumors translates to patients, suggesting that these mouse
models could help identify sub-groups of patients who would
most benefit from a specific treatment.
RESULTS
Mouse HGSOC Models
As >98% of HGSOC are TP53 null or have TP53 mutations and
50% have defects in homologous double-stranded DNA
(dsDNA) repair, we focused on models with key genotypes.
Details of the genetic mutations, latency, and distribution of me-526 Cell Reports 30, 525–540, January 14, 2020tastases of the individual models are summarized in Figure 1A
and Table S1A. Cell lines 30200 and 60577, originally developed
from GEMMs of serous ovarian cancer (Szabova et al., 2014),
which had been engineered to be Trp53/, Brca1/, and ex-
pressed TAg121 (the N-terminal domain of SV40 T antigen), under
control of the cytokeratin 18 promoter, to inactivate the tumor
suppressor function of Rb. These models are syngeneic in FVB
mice and originate from the ovarian surface epithelium.
Following intraperitoneal (i.p.) injection, they produced extensive
omental and peritoneal metastases, with established disease
detected at 20 weeks (30200) and 6 weeks (60577).
We also used another GEMM, developed by Perets et al.
(2013), with Pax8-Cre driving inducible inactivation of Brca2,
Trp53, and Pten (Brca2/;Trp53/;Pten/ or Brca2+/;
Trp53/;Pten/) in the fallopian tube. We extensively back-
crossed these various GEMMs to the B6 background and estab-
lished four polyclonal tumor cell lines, HGS1–4, from fallopian
tube, ovary, or peritoneal tumors that developed in the induced
backcrossed mice (details in Table S1A). When injected i.p., all
of the HGS cell lines produced omental tumors and metastases
to splenoportal fat, lesser omentum, and mesentery, with
extensive disease established by 12–20weeks (Figure 1B). Other
metastatic sites were ovaries, fat surrounding the reproductive
tract, liver, and diaphragm.
Tumors from the six cell lines had serous histology (Figure 1B)
presenting as high-grade carcinomas arranged in solid sheets,
with cells displaying spindle-like morphology (Figures S1A and
S1B). Nests and papillae were occasionally present (Figure S1C).
The malignant cells were pleomorphic with a high nuclear:cyto-
plasmic ratio and frequent mitoses (Figure S1D). The nuclei
were irregular, and nucleoli were variably prominent (Figure S1D).
Apoptosis was conspicuous, and some tumors exhibited necro-
sis (Figure S1E). There was occasional dystrophic calcification
and evidence of muscle invasion (Figures 1B and S1F). All of
these features are consistent with high-grade serous carcinoma.
Transcriptomic Analysis of Murine Tumors
Using RNA sequencing (RNA-seq), we analyzed the transcrip-
tome of peritoneal tumors from the six models plus three ‘‘pri-
mary’’ tumors from the backcrossed GEMM (Perets et al.,
2013) and normal omentum from FVB and B6 mice. We chose
the omentum because it is a distinct structure that is easy to
identify and dissect in the mouse. Moreover, omentum is a major
site of metastasis in human disease (Nieman et al., 2011), andwe
had already conducted extensive multi-level analyses of human
HGSOC omenta (Pearce et al., 2018). Accordingly, the majority
of mouse tumors studied were from the omentum.
We analyzed RNA-seq data from three to five tumors per
model, harvested when mice with extensive peritoneal disease
reached a humane endpoint. A total of 14,201 protein-coding
genes were sufficiently detected. Principal-component analysis
(PCA) segregated the samples into three groups (Figure 1C).
Control FVB and B6 omenta were in a distinct cluster from the
FVB tumors 60577 and 30200. Tumors from the GEMM and
HGS1–4 were grouped into a third cluster. A cluster dendrogram
confirmed the distinct groups and close association of the HGS
tumors with the GEMM (Figure S1G). We observed sub-clus-
tering of HGS1, 3, and 4, while HGS2 was interspersed among
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Figure 1. Characterization of Murine HGSOC Models
(A) Overview of murine models and the analyses conducted.
(B) Left panel: gross anatomy of the tumor distribution in the peritoneal cavity of a mouse injected with the HGS2 cell line and culled at a humane endpoint.
Omental (O), mesenteric (M), and splenoportal (SP) tumor deposits are highlighted with a dashed line. A metastasis to the liver surface is indicated by an arrow.
(legend continued on next page)
Cell Reports 30, 525–540, January 14, 2020 527
HGS1 and 4, indicating that despite similarity among the HGS
models, they retain some distinct transcriptomic features.
A total of 1,292 transcribed genes were significantly ex-
pressed (false discovery rate [FDR] < 0.05) in tumors from each
of the models compared with normal omentum (Figure S1H).
Enrichment analysis of these revealed common pathways
altered in all of the murine peritoneal tumors compared with
normal omentum, including TME-related pathways such as
regulation of cytokine secretion, response to mechanical stim-
ulus, transforming growth factor b (TGF-b) stimulation, hypoxia,
ECM-receptor interactions, wound healing, immune and inflam-
matory responses, and angiogenesis (Figure 1D). As expected,
other enriched pathways—for instance, cell proliferation, chro-
mosome segregation, and development—were also featured
(see complete list in Table S1B).
This analysis demonstrates that the TMEs of the individual
mouse models exhibit common and distinct molecular features
and that the enrichment of key pathways associated with im-
mune response and the matrisome are over-represented in the
transcriptomes.
Comparison of CNA in Mouse and Human Tumors
The Cancer Genome Atlas (TCGA) and International Cancer
Genome Consortium (ICGC) sequencing have identified recur-
rent copy number alteration (CNAs) in HGSOC (Macintyre
et al., 2018). To establish whether concordant CNAs existed be-
tween human disease and themousemodels, we extracted DNA
from mouse tumors and cell lines and performed array compar-
ative genomic hybridization (aCGH) copy number analysis. This
identified genomic regions of recurrent gain and loss and
included some of the top 20 significant recurrent CNAs in the
TCGA database of human HGSOC (Figure 1E; Table S1C). Re-
gions showing consistent amplification includedMyc and genes
associated with RNA processing, the PI3K pathway, the
mammalian target of rapamycin (mTOR), and NOTCH signaling
(Figures 1F and S1I) in agreement with findings in the original
GEMM (Perets et al., 2013).
Comparison of Transcriptomes of Human and Mouse
HGSOC Metastases
Having established concordance between human HGSOC tu-
mors and the mouse models at the genomic level, we compared
the transcriptomic profiles of established murine tumors with
pre-treatment omental metastases from nine HGSOC patients.
There was a significant correlation between the expression
levels of orthologous genes in the murine tumors and human
tumors (Figure 2A). Figure 2A also shows strong similarities
between the 30200 and 60577 tumor lines and among the four
HGS models and their respective GEMM tumors, as expected
from Figure 1. The top concordant gene expression patternsCenter and right panels: tissue sections were derived from normal omenta (Bl6Om
and GEMM) and stained with hematoxylin and eosin (scale bars, 100 mm).
(C) Unsupervised clustering of RNA-seq sample groups by principal-component
(D) Significantly enriched Gene Ontology (GO) terms and pathways (p < 0.001) in
(E) Genomic alterations found in murine HGSOC. Copy number losses and gain
altered in human HGSOC, are indicated with blue for losses and red for gains.
(F) OncoPrint showing genes with high mutation frequency in TCGA and present
528 Cell Reports 30, 525–540, January 14, 2020between human and mouse peritoneal tumors are shown in Fig-
ure 2B (full list in Table S2A). Of particular interest wasCOL11A1,
one of the six upregulated molecules in the Matrix Index (Pearce
et al., 2018) that was also identified in a human pan-cancer gene
signature of activated fibroblasts (Jia et al., 2016). We also noted
enhanced expression ofRUNX2, a transcription factor shared by
amajority of genes in theMatrix Index (Pearce et al., 2018). Other
commonly expressed genes of interest were the VDR, identified
as a master transcription factor of stellate cells in pancreatic
ductal adenocarcinoma (PDAC) (Sherman et al., 2014), and
FOLR1, which is commonly overexpressed in ovarian cancer
and a target for immunotherapy (Bergamini et al., 2016). Protein
expression of these geneswas confirmed by immunohistochem-
istry (IHC) (Figure S2). Using IHC, COL11A1, RUNX2, and VDR
were primarily detected in the stroma, with some malignant
cell positivity. FOLR1 was highly expressed on malignant cells.
We then looked inmore detail at signaling pathways and found
strong correlations between murine and human tumors in terms
of the p53 and DNA-damage repair pathways; the mTOR, ErbB,
and Hippo pathways; and cell-cell communication and tumor
necrosis factor receptor 2 (TNFR2) non-canonical nuclear factor
kB (NF-kB) signaling (Figure 2C). Several other common path-
ways included FoxO, nucleotidemetabolism, estrogen signaling,
semaphorin interactions, ECM, cell-junction organization, c-type
lectin receptors, adherens junctions, and deactivation of b-cate-
nins (Table S2B).
Biological processes significantly represented in both the
mouse and human peritoneal tumors included wound healing,
ECM organization and disassembly, immune response, angio-
genesis, and malignant cell signaling pathways (Figure 2D).
In conclusion, metastases from human and murine tumors
shared many common pathways and processes related to
both the malignant cells and their interactions within the TME.
Having identified common pathways between human and
mouse omental metastases, we wanted to see how mouse
omental metastases compared with primary HGSOC tumors.
Analysis of Mouse and Human Tumor Transcriptomes
To further characterize transcriptional programs preserved be-
tween mouse and human HGSOC tumor transcriptomes, we
performed weighted correlation transcriptional network analysis
(WGCNA) (Langfelder and Horvath, 2008; Bailey et al., 2016) on
the ICGC HGSOC dataset of primary pre-treatment tumors
(Patch et al., 2015). This analysis identified 18 coordinately
expressed gene programs associated with distinct biological
pathways and/or processes (Figure 3A; Tables S3A–S3G). The
gene programs were significantly enriched for immune cell-spe-
cific genes associated with B cell and CD8+ signatures or with
macrophage genes and T cell co-inhibition (Figure 3B). We
also identified a program enriched for antigen processing ande and FVBOme) andmousemodel tumors (60577, 30200, HGS1, HGS2, HGS3,
analysis.
the common 1,292 differentially expressed genes.
s are shown in blue and red, respectively. Key orthologous genes, frequently
in CNA regions in mouse models.
A B
C D
Figure 2. Comparison of Murine HGSOC and Human Omental Metastasis Transcriptomes
(A) Upper triangle: Pearson correlation coefficients based on the average expression (reads per kilobase million [RPKM]) of 12,127 orthologous genes in pairwise
alignments of human omental tumors and mouse model tumors. Lower triangle: the diameter of the ellipses is proportional to the correlation coefficient; thinner
ellipses correspond to higher correlation coefficients.
(B) Top concordantly upregulated genes in murine HGSOC and human omental tumors (FDR < 0.05).
(C and D) Key signaling pathways (C) identified by pathway analysis through Gaussian graphical models (clipper, pathway threshold p < 0.05), concordant in
human and all mousemodel tumors and biological processes (D) and significantly altered in bothmurine and humanHGSOC (hypergeometric test p < 0.05). Cycle
diameter proportional to adjusted p value; color corresponds to pathway Z score.
(A–D) 30200, HGS2, and HGS3, n = 4; 60577 and HGS4, n = 5; HGS1, n = 3; FVBOme, n = 4; Bl6Ome, n = 5. For human samples, n = 9 normal/adjacent omenta
and n = 9 omental tumors.
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Figure 3. Comparison of Murine HGSOC and ICGC Ovarian Transcriptomes
(A) Weighted correlation network analysis (WCNA) of human ICGC transcriptional HGSOC dataset showing clusters of co-regulated genes as a dendrogram.
Colors show different modules (gene programs).
(B) Cluster dendrogram of module eigenvalues (MEs) illustrates clustering of programs associated with ECM, immune response, or tumor-related signaling
pathways.
(C) Heatmap of MEs across ICGC samples (n = 93).
(D) Heatmap of association of C1–C5 classification. Positive associations are shown in red and negative associations are shown in blue. Pearson’s r and p values
are indicated in the fields where a significant association was observed (p < 0.05).
(E) Heatmap of association of differentially expressed gene scores in mousemodels. Positive associations are shown in red and negative associations are shown
in blue. Pearson’s r and p values are indicated in the fields where a significant association was observed (p < 0.05).presentation, including high expression of Toll-like receptor
genes (e.g., TLR4/7/8/PDL2, CSF1R) (Figure 3B). As expected,
there was heterogeneity in the expression patterns of transcrip-
tional programs across patient tumors (Figure 3C).
Next, we correlated the 18 gene programswith the C1–C5mo-
lecular signatures identified in primary human HGSOC biopsies
(Leong et al., 2015). C1 represents the mesenchymal subtype,
and it strongly correlated with the ECM-enriched program
(MEred, Figures 3B and 3D). C2 represents the immunoreactive
subtype associated with the immune gene programs (MEcyan
and MEyellow, Figures 3B and 3D). C3–C5 showed associations
with other distinct sets of programs.530 Cell Reports 30, 525–540, January 14, 2020We then asked whether there was any association between
18 identified gene programs in the human primary tumors
and the mouse tumors. ECM and immune response processes
were the most significantly preserved gene programs across all
of the models (Figure 3E). The HGS tumors associated more
strongly with the ECM program (MEred) compared with the
30200 and 60577 tumors. However, the 30200 and 60577 tu-
mors associated more strongly with the immune programs
than the HGS models. Thus, despite the similarities between
the mouse models, we were able to identify a number of cell
line-specific TME characteristics. These results were indepen-
dently verified using a consensus network obtained from the
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Figure 4. Immune Cells and Vasculature of the Murine and Human HGSOC
(A) Proportions of immune cell populations estimated from murine tumors and human omental metastases using CIBERSORT. 30200, HGS2, and HGS3, n = 4;
60577 and HGS4, n = 5; HGS1, n = 3; human omental tumors, n = 9. Median values are depicted.
(B) Flow cytometric analysis of the immune infiltrate of peritoneal tumors, close to endpoint, from mice injected with 60577, 30200, or HGS cell lines. B cells:
CD45+ CD19+, CD4 cells: CD45+ CD3+ CD4+, CD8 cells: CD45+ CD3+ CD8+, monocytes: CD45+ CD11b+ Ly6C+, macrophages: CD45+, CD11b+ F4/80+
(Ly6C/G), granulocytes: CD45+ CD11b+ Ly6G+, CD11c+ cells: CD45+ CD11b+ CD11c+ (F4/80 Ly6C/G). A similar analysis of the immune infiltrate in the
diseased omentum from patients who underwent upfront surgery is shown for comparison (HuHGS).
(legend continued on next page)
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TCGA ovarian transcriptomic data (Figure S3; Tables S4A–
S4E).
Our data indicate that the mouse models share transcriptional
patterns that are present in human HGSOC TMEs and primarily
replicate the mesenchymal and immunoreactive human HGSOC
subtypes.
Immune Cell Profiles of the Murine and Human HGSOC
Tumors
To identify immune cell types and/or phenotypes associated
with murine tumors or pre-treatment human omental metasta-
ses, we used CIBERSORT (Newman et al., 2015) to interrogate
the transcriptomic data (Figure 4). According to the CIBERSORT
analysis of the orthologous genes, all of the murine and human
tumors contained significant populations of B cells, CD4+ and
CD8+ T cells, monocytes, and macrophages (Figure 4A). Genes
associated with resting dendritic cells, neutrophils, and natural
killer (NK) cells were variably expressed. The profile of HGS1
most closely resembled human HGSOC metastases.
We then conducted flow cytometry on dissociated murine and
human tumors to validate these results (Figure 4B). There were
detectable populations of macrophages, monocytes, B cells,
granulocytes, and CD4+ T cells in the murine tumors with small
populations of CD8+ T cells and CD11c+ dendritic cells. Heavily
diseased human HGSOC omental samples had higher numbers
of T cells and fewer myeloid cells than the murine tumors. We
also assessed the density of T cells by IHC for CD3+ T cells (Fig-
ure 4C) using Definiens Tissue Studio software. There was a vari-
ability in CD3+ T cell density, which reflected the variability in the
human omental metastases also seen in other studies of primary
HGSOC (Zhang et al., 2018) and our published data on HGSOC
omental metastases (Bo¨hm et al., 2016; Pearce et al., 2018). The
rangewas similar betweenmouse and human tumors, but overall,
therewere fewer CD3+ T cells in themouse tumors comparedwith
the human samples (p < 0.001), although there was no difference
between 60577 mouse tumors and the human tumors. Similarly,
using IHC, we compared the density of F4/80+ and CD68+macro-
phages inmurine tumorsandhumanomentalmetastases, respec-
tively (Figure 4D). In agreement with the CIBERSORT RNA anal-
ysis, 60577 tumors had the lowest density of F4/80+ cells, which
was particularly interesting as they had the highest CD3+ T cell
density of all of the murine tumors. F4/80+ cell densities were
similar across the rest of themurine tumorsbut,with the exception
of 60577 tumors, were at a higher density than the levels in the
human omental metastases studied here (p < 0.001). There was
no significant difference between 60577 and the human tumors.
Vasculature of Murine and Human HGSOC Tumors
As the vasculature of HGSOC is also an important therapeutic
target (Oza et al., 2015), we quantified blood vessels in the mu-(C) Quantification of the number of CD3+ cells/mm2 by IHC on peritoneal tumors f
cells in biopsies from patients (HuHGS) is shown for comparison. Representative
(D) Quantification of the percentage of an area positive for F4/80 by IHC on
Quantification of CD68+ area in patient biopsies is included for comparison. Rep
(E) IHC for endomucin (mouse) and CD31 (human) staining, quantified using the D
dot represents a tumor from an individual mouse or human. Representative imag
(F) Heatmap illustrating Gene Ontology biological process angiogenesis gene ex
532 Cell Reports 30, 525–540, January 14, 2020rine omental tumors using Definiens Tissue Studio after IHC for
endomucin and compared this to the density of CD31+ blood
vessels in human HGSOC omental metastases (Figure 4E).
Both the average size and density of vessels with lumens were
similar in murine and human omental metastases. IHC images
(Figure 4E) show similar vessel structures and distribution in
the reactive stroma around malignant areas (top images) and
within the malignant areas (bottom images). Figure 4F shows
theGeneOntology biological pathway heatmap for angiogenesis
in murine and human tumors. Here, the pattern of expression of
angiogenic genes in the human biopsies seems to be amix of the
different murine tumors, and while 60577 seems to have a
distinct gene expression pattern, this did not affect vessel den-
sity or size. The pattern of angiogenic gene expression was
also variable in the primary HGSOC tumors (Figure S4).
Matrisome, Matrix Index, and Fibroblasts
As one of the aims of this study was to determine whether mouse
tumors reproduce the prognostic matrisome gene expression
patterns we found in human HGSOC (Pearce et al., 2018), we
studied the pattern of matrisome gene expression in the mouse
and human omental tumor biopsies and normal omenta. This
analysis showed enhanced expression of collagens, matrisome
glycoproteins, proteoglycans, ECM regulators, and ECM-
secreted factors in both mouse and human tumors compared
with control omenta (Figure 5A). There were also differences be-
tween the mouse models, especially between the HGS tumors
and 60577 or 30200. In general, the murine tumors recapitulated
our findings in human tumors, as shown by an increased expres-
sion of genes across all of the matrisome classes. Murine 60577
and 30200 tumors were unusual in upregulating more genes
associated with small-molecule-secreted factors (shown in
ECM-secreted factors and ECM regulators), rather than larger
fibular components (e.g., collagens, proteoglycans), which
were more similar to normal tissue (Figure 5A).
We then asked whether the murine tumors had similar values
for the prognostic Matrix Index that we previously identified in
the human omental metastases, primary HGSOC, and 12 other
human solid cancer datasets (Pearce et al., 2018). The 22 Matrix
Index genes (Table S5) were all expressed the mouse tumors.
However, levels varied between low in 60577 to high in HGS1,
thus showing variations in the Matrix Index (Figure 5B, left panel)
that were similar to the range of values seen in diseased pre-
treatment human omental HGSOC metastases (Figure 5B, right
panel).
We then used mechanical indentation (Delaine-Smith et al.,
2016) to measure tissuemodulus (ameasure of material stiffness
independent of sample dimension). Tissuemodulus values of the
mouse tumors were one to two orders of magnitude higher than
the normal human or mouse omentum (Figure 5C, left panel) androm mice injected with 60577, 30200, or HGS cell lines. Quantification of CD3+
images are shown; scale bars set to 100 mm.
peritoneal tumors from mice injected with 60577, 30200, or HGS cell lines.
resentative images are shown; scale bars set to 100 mm.
efiniens Tissue Studio platform with the blood vessel detection feature. Each
es for HGS2 and HuHGS are depicted at left. Scale bars, 100 mm.
pression across mouse models and human omental tumors.
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Figure 5. Matrisome, Matrix Index, and Stiffness of Murine and Human HGSOC
(A) Heatmap of orthologous matrisome genes, grouped bymatrisome class, in themouse and human peritoneal datasets compared to normal omenta (Student’s
t test, p < 0.05).
(legend continued on next page)
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were in a range similar to that of diseased pre-treatment human
HGSOC omentum (Figure 5C, right panel) values we have
recently published (Pearce et al., 2018).
In our previous study of human HGSOCmetastases, we found
a high correlation between the density of fibroblastic cells posi-
tive for a-smooth muscle actin (aSMA) and the tissue modulus of
the sample. In keeping with this finding, mouse tumors with the
highest levels of aSMA were among the stiffer tumors with a
higher Matrix Index (Figures 5B and 5D).
There were six matrisome molecules whose upregulation was
associated with disease score and high tissue modulus in the
human Matrix Index: fibronectin 1 (FN1), versican (VCAN), colla-
gens 1A1 and 11A1 (COL1A1 and COL11A1), cathepsin B
(CTSB), and cartilage oligometric matrix protein (COMP) (Pearce
et al., 2018). All six were detected by IHC in mouse tumors but at
varying levels. Figure 5E shows that Masson’s trichrome staining
for collagen followed a similar pattern to the data from Figures
5A–5D. Figure 5F shows the quantification of FN1 and VCAN
staining in mouse tumors. The other four matrisome proteins
were also detected by IHC (for representative images, see Fig-
ure S5). Overall, the strongest staining in all of the tumors was
seen with FN1, VCAN, and CTSB, and the weakest for COMP.
Using sequential sections from the murine tumors, we then
constructed a tissue matrisome heatmap of these six proteins
using color deconvolution (Schneider et al., 2012; Ruifrok and
Johnston, 2001). In some tumor areas, all six proteins were at
high density. In Figure 5G, this is shown as absence (black) or
the co-localization in situ of one (dark blue), two (cyan), three
(green), four (yellow), five (orange), or six (red) matrisome mole-
cules. HGS2 tumors had the highest number and areas of co-
located molecules.
Overall, we find significant similarities between the mouse
peritoneal tumors, human omental metastases, and primary
human pre-treatment HGSOC tumors, especially in relation to
immune and matrisome components. We believe that the
models described above could be useful for the pre-clinical eval-
uation of TME-targeted therapies. However, each of our models
had distinct characteristics and vulnerabilities, which are
influenced by the mutations, tissue of origin, strain background,
and genomic instability. We hypothesized that these ‘‘vulnerabil-
ities’’ could be exploited therapeutically and that our HGSOC
models would exhibit a range of different responses that reflect
the range seen in patients.(B) Matrix Index of murine and human peritoneal HGSOC and normal omenta. 302
Bl6Ome n = 5. For human samples, n = 9 normal/adjacent omenta and n = 9 om
(C) Tissue modulus of murine and human peritoneal HGSOC and normal oment
correspond to the Kruskal-Wallis test for mouse data and the Mann-Whitney U t
(D) Fibroblast content of murine and human peritoneal HGSOC and normal omen
Tissue Studio platform. p values correspond to one-way ANOVA. Each dot repre
depicted at right. Scale bar, 50 mm.
(E) Masson’s trichrome staining was performed on all HGSOC model tumors an
quantification of the percentage of positive area by the Definiens Tissue Studio.
100 mm. p values correspond to one-way ANOVA. Each dot represents a tumor
(F) IHC for FN1 and VCAN staining quantified using the Definiens Tissue Studio pl
from an individual mouse. Representative images for HGS1 are depicted at right
(G) Construction of tissuematrisome heatmaps formodels of HGSOC. Serial IHC i
highlight areas that were rich (red) or poor (black) in ECM. Expression hotspots fo
ECM molecules are presented with the different colors on the key map shown at
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HGSOC Models
To investigate the above hypothesis and assess the suitability of
our models for pre-clinical studies, we used the RNA-seq data to
define in more detail the differences between the mouse models
using the normal mouse omenta as controls. As expected, fatty
acid biosynthesis and adipocytokine signaling expression path-
wayswere significantly higher in the normal omenta compared to
omental tumors. Conversely, Myc, cell-cycle, and Tp53 path-
ways weremore dominant in the tumors compared to the normal
omenta (Figure 6A). Of particular interest were significantly
higher levels of cell-cycle pathways in the 60577 tumors
compared to all of the other tumors, higher expression of the
interleukin-6 (IL-6) pathway in the 30200 tumors, and higher
expression of matrisome and integrin pathways in the HGS
tumors (Figure 6A). Were the gene expression differences asso-
ciated with response to therapy?
To test this hypothesis, we looked in more detail at the DNA
replication gene expression heatmap, and based on the data
shown in Figure 6B and the immune cell profiles in Figure 4C,
we predicted that established 60577 tumors would be more
responsive to carboplatin chemotherapy than HGS2. Survival
of 60577-bearing mice was increased 5-fold by platinum treat-
ment compared to <2-fold for HGS2-bearing mice (Figure 6C).
Next, we wanted to test a treatment that may modify the TME.
In view of our previous pre-clinical and clinical data on IL-6 as a
TME regulator in HGSOC (Coward et al., 2011; Stone et al.,
2012), we looked in more detail at IL-6-regulated genes. We
found that the 30200 tumors had the highest expression of genes
in this pathway, while HGS2 and 60577 were lower (Figure 6D).
We treated established tumors from three different models
with anti-murine IL-6, and only in 30200 did we find significant
modulation of the TME after treatment with an anti-IL-6 antibody.
Specifically, after treatment for 5–7 weeks, there was a signifi-
cant decrease in F4/80+ macrophages. Concomitant with this
decrease in tumor-associated macrophages (TAMs), we noted
a significant increase in CD3+ T cells. There was also a trend
toward a decrease inmacrophagemannose receptor expression
in 30200 omental tumors (Figure 6E), suggesting a decline in
tumor-promoting TAMs.Mice in the anti-IL-6-treated groups first
reached the endpoint 5 weeks after the isotype-control mice,
and there were long-term survivor mice in the treated group
when the experiment was terminated at 56 weeks (Figure 6E).00, HGS2 andHGS3, n = 4; 60577 andHGS4, n = 5; HGS1 n = 3; FVBOme n = 4;
ental tumors.
a. Each dot represents a tumor from an individual mouse or patient. p values
est for human data.
ta was assessed by IHC for aSMA staining and quantified using the Definiens
sents a tumor from an individual mouse. A representative image for HGS1 is
d on normal omenta. Bar plot illustrates the result of digital analysis and the
Representative images for 60577 and HGS1 are depicted at right. Scale bars,
from an individual mouse.
atform. p values correspond to one-way ANOVA. Each dot represents a tumor
. Scale bars, 100 mm.
mageswere color deconvoluted, overlaid, and pseudo-colored using ImageJ to
r all six ECMmolecules are shown in red, whereas areas expressing one to five
right. Scale bars, 1 mm.
AB C
D
E
F
Figure 6. Therapeutic Vulnerabilities of HGSOC Models
(A) Single-sample gene set enrichment analysis (GSEA) was performed for the murine HGSOC transcriptomes. Heatmap illustrates pathway scores with distinct
expression patterns in 30200, 60577, HGS tumors, and normal omenta (FDR < 0.05). 30200, HGS2, and HGS3, n = 4; 60577 and HGS4, n = 5; HGS1, n = 3;
FVBOme, n = 4; Bl6Ome, n = 5.
(legend continued on next page)
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There was no effect on macrophages or T cells in the omental tu-
mors in similar experiments conducted on established HGS2 tu-
mors (Figure 6F) and established 60577 tumors and no effect on
survival in HGS2-bearing mice (survival not assessed in the
60577 model) (Figure S6).
Multivariate Classification of Patient Response Based
on Mouse Model Data
Finally, we asked whether the mouse model data had relevance
for the chemotherapy responses of HGSOCpatients. Comparing
the pre-treatment transcriptomes of the carboplatin-sensitive
60577 tumors with less sensitive HGS2 tumors, we identified
genes that were differentially expressed (FDR < 0.0001, log
fold change >j3j). Of these, 687 had human orthologs in the
ICGC dataset of primary pre-treatment HGSOC tumors (Fig-
ure 7A; Table S6A). As chemotherapy outcomes are available
for ICGC patients, we applied a multivariate classification tool
(classyfire) (Chatzimichali and Bessant, 2016) that provides a
state-of-the-art open source pipeline for the construction of
robust classification models and implements support vector ma-
chine (SVM) ensemble classifiers with automated bootstrap
training and permutation testing. We used classyfire to assess
the relation between the expression pattern of the 687 genes
and patient responses, as recorded in the ICGC dataset
(Figure 7B).
classyfire correctly predicted responses in 70% of the ICGC
patients. This value was an average across 50 SVM models
within the ensemble, each of which was trained using 100 boot-
strap repetitions (Figure 7C). Figure 7D illustrates that a stable
classification ensemble, in which the accuracy of individual clas-
sifiers averaged out, was achieved after 40 SVMs, which jus-
tifies choosing 50 SVMs in this analysis. Statistical significance,
assessed by permutation testing with the number of permuta-
tions set to 100, indicated that the accuracy of the dataset was
significantly higher than random chance (p < 0.001). Enrichment
analysis showed that within the 687 gene patterns derived from
the mouse tumors, patient resistance to chemotherapy was
significantly associated with ECM organization, cell adhesion,
and collagen catabolism and organization (Figure 7E; Table
S6B). Our analysis indicates that transcriptional features of the
mouse models that associate with chemotherapy response are
also present in humans and are predominantly related to the tu-
mor microenvironment.
DISCUSSION
As there are multiple immune and other TME targets in HGSOC,
there is a pressing need for pre-clinical models that allow the
assessment of new therapies, especially in combination. We(B) Heatmap of REACTOME DNA replication pathway genes across the murine t
(C) Response ofmice injectedwith 60577 or HGS2 to three cycles of chemotherap
shown (n = 5 mice per group). The log rank p value is depicted on the survival cu
(D) Heatmap of BIOCARTA IL-6 pathway genes across the murine tumors.
(E and F) Mice injected with 30200 (E) or HGS2 (F) were treated with isotype contr
after cell injection until endpoint. The log rank p value is depicted on the surviva
ntreated = 12). Analysis of the immune infiltrate was performed by flow cytometry o
Each dot represents a tumor from an individual mouse. For 30200, two experime
536 Cell Reports 30, 525–540, January 14, 2020set out to determine whether transplantable orthotopic models
in immunocompetent mice would replicate some of the impor-
tant molecular, cellular, and biomechanical features of the hu-
man diseased TMEs, as most previous studies have focused
on the epithelial compartment. We had two advantages with
these HGSOC models: first, we had previously conducted an
extensive multi-level analysis of human HGSOC omental metas-
tases (Pearce et al., 2018), and second, as we injected the
murine cancer cells i.p., we were replicating the peritoneal
dissemination that is thought to occur in human disease. We
used polyclonal cell lines as we believe that they better reflect
the intra-tumoral heterogeneity that is present in patients.
Although the murine cell lines only represented one group of
HGSOC (i.e., those with dsDNA repair defects), there were
significant correlations with pre-treatment human omental
metastases and with primary tumors from the TCGA and ICGC
datasets independent of whether the patient samples were
DNA damage repair (DDR) deficient. Themost commonly shared
pathways related to the TME, especially in the matrisome and
cell adhesion. This suggests that dsDNA repair defects are not
major determinants of the TME, although BRCA1 mutations
are associated with higher T cell counts in patients (Clarke
et al., 2009). Our tumor models recapitulate the CNAs that are
the hallmark of HGSOC. The present study therefore highlights
the importance of cell context and genomic content in mouse
models—in other words, the correct genes in appropriate cell
types give rise to tumors that recapitulate important components
of the human TME. However, it is important to point out that
60577 and 30200 tumors were derived from the ovarian surface
epithelium rather than the fallopian tube, although contemporary
research strongly supports the fallopian tube origin (Karnezis
et al., 2017). In addition, these tumors were syngeneic in FVB,
whereas the HGS lines were syngeneic to B6.
Because we had extensively studied omental metastases in
patients, we focused on murine omental metastases for many
of our analyses, but there were significant correlations with
primary tumors in all of the transcriptional data, suggesting
that the tissue site does not necessarily influence the compo-
sition of the TME. This is also clear in studies of multiple
human HGSOC biopsies from individual patients (Zhang
et al., 2018).
One notable finding was the list of genes that were overex-
pressed in human and murine tumors compared to normal
omentum, four of which we validated by IHC and flow cytometry.
The top 40 genes are shown in Figure 2B, but there are 154more
that can be further studied, if confirmed at the protein level.
Some of the commonly overexpressed genes were already
known as therapeutic targets in ovarian and other cancers. For
instance, folate receptor a is overexpressed by many humanumors.
y (carboplatin 20mg/kg, once per week). Survival curve andmedian survival are
rves. The start of the treatment is indicated by the red arrow.
ol or anti-IL-6 i.p. 2 mg/kg twice weekly starting 10 (30200) or 7 (HGS2) weeks
l curves (for 30200, ncontrol = 16 and ntreated = 11; for HGS2, ncontrol = 11 and
n a different set of mice and Student’s t test value is depicted on the bar plots.
nts pooled together are shown.
A B
C D
E
Figure 7. Multivariate Classification of Patient Response Based on Mouse Model Data
(A) Heatmap of 687 differentially expressed genes in 60577 (n = 5) versus HGS2 (n = 4) tumors (FDR < 0.0001, log fold change (FC) > |3|).
(B) Schematic of multivariate classification implemented with R package classyfire on ICGC data, using the 687 genes for the prediction of chemotherapy
response. The 80 primary tumor samples of the ICGC dataset were used in this analysis.
(C) Bar plot illustrating the result of the classification ensemble accuracy on predicting class membership of previously unseen samples.
(D) Average test accuracy in relation to the number of support vector machine (SVM) ensembles used.
(E) Heatmap of the topGO biological processes enriched in the 687 genes (adjusted p < 0.05). adjp (adjusted p value),log10; nAnno, number of genes in the gene
set; nOverlap, number of overlapping genes between gene set and 687 gene list. Red squares denote genes in the top enriched GO processes. A maximum of
15 overlapping genes are shown for GO processes with nOverlap >15.HGSOC cells and is now a target for antibody and chimeric an-
tigen receptor (CAR) T cell therapies (Bergamini et al., 2016;
Zhu et al., 2017). The vitamin D receptor is identified as a master
transcription factor of stellate cells in PDAC (Sherman et al.,
2014). Our previous work identified RUNX2 as a transcription
factor that is common to a majority of the prognostic Matrix In-
dex genes described earlier (Pearce et al., 2018). RUNX2 also
plays important roles in the Hippo signaling, a pathway impli-
cated in the regulation of tissue stiffness and signal transduction
from the ECM as well as HGSOC progression (Passaniti et al.,
2017). Another potential target, shared by the mouse and human
tumor samples, is SLC34A2. Its protein product, NaPi2b, a type II
sodium phosphate transporter, is highly expressed on the sur-
face of ovarian and other malignant cells and is exploited in anti-
body-drug conjugates (Lin et al., 2015). The ability to delete
genes of interest in our cell line-based tumor models will enable
us and others to further understand the biology and therapeutic
potential of individual targets.There are also some notable differences between the mouse
and human tumors that must be considered in translating pre-
clinical studies. Probably the most important difference was
higher numbers of TAMs and lower numbers of CD3+ T cells,
with a higher proportion of CD4+ cells in the mouse versus hu-
man as this could influence immunotherapy response.
It is interesting that the common gene pathways that classified
responses to chemotherapy in both human and mouse HGSOC
were associated with cell adhesion and ECM and not DNA dam-
age response or adaptive immune cell pathways. We can spec-
ulate that this means that less drug and/or fewer immune cells
are able to reach malignant cell areas during chemotherapy,
leading to a reduced response.
In conclusion, these orthotopic transplantable models may
provide useful pre-clinical tools and help identify subgroups of
HGSOC patients most likely to respond to specific therapies.
The HGS cell lines are freely available, and all of the data asso-
ciated with this paper is available at www.canbuild.org.uk.Cell Reports 30, 525–540, January 14, 2020 537
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Rat anti-mouse CD45-BV785 (Clone 30-F11) Biolegend Cat# 103149; RRID:AB_2564590
Armenian hamster anti-mouse CD3-PE-Cy7
(Clone 145-2C11)
Biolegend Cat# 100320; RRID:AB_312685
Rat anti mouse CD4-BV605 Biolegend Cat#100548; RRID:AB_2563054
Rat anti-mouse CD8a-APC (Clone 53-6.7) eBioscience Cat# 17-0081-83; RRID:AB_469336)
Rat anti-mouse/human CD11b-BV650 (Clone M1/70) Biolegend Cat# 101239; RRID:AB_11125575)
Armenian hamster anti-mouse CD11c-FITC,
(Clone N418)
eBioscience Cat#11-0114-82; RRID:AB_464940
Rat anti-mouse F4/80-PE (Clone BM8) Biolegend Cat#123110; RRID:AB_893486
Rat anti-mouse Ly6C -eFluor450 (Clone HK1.4) eBioscience Cat#48-5932-82; RRID:AB_10805519
Rat anti-mouse Ly6G(Gr1)-AF700 (Clone RB6-BC5) eBioscience Cat#56-5931-82; RRID:AB_10805519
Rat anti-mouse CD19 PerCP-Cy5.5 (Clone 6D5) eBioscience Cat#115534; RRID:AB_2072925
Rat anti-mouse I-A/I-E- APC-Cy7 (Clone M5/114) Biolegend Cat#107628; RRID:AB_2069377
InVivoMAb anti-mouse IL-6 BioXCell Cat#BE0046; RRID:AB_1107709
InVivoMAb rat IgG1 isotype control, anti-
horseradish peroxidase
BioXCell Cat# BE0088; RRID:AB_1107775
F(ab’)2-Goat anti-Rat IgG (H+L) Highly Cross-
Adsorbed Secondary HRP
Thermo Fisher Cat# A24555; RRID:AB_2536023
Goat anti-rabbit biotinylated IgG Vector Laboratories Cat# BA-1000; RRID:AB_2313606
Anti-rat IgG Vector Laboratories Cat# BA-4001; RRID:AB_10015300
Anti-mouse IgG Vector Laboratories Cat# BA-2000; RRID:AB_2313581
Rat monoclonal anti-CD3 Abcam Cat# ab11089; RRID: AB_369097
Rabbit polyclonal anti-human CD3 Agilent Cat# A0452; RRID: AB_2335677
Rat monoclonal anti-F4/80 Serotec/BioRad Cat# MCA497; RRID:AB_2098196
Rat monoclonal anti-endomucin (V.7C7) Santa Cruz Biotechnology Cat# sc-65495; RRID:AB_2100037
Mouse monoclonal anti-PECAM-1 (0.N.100) Santa Cruz Biotechnology Cat# sc-71872; RRID:AB_1125653)
Rabbit polyclonal anti-actin, smooth muscle Abcam Cat# ab5694; RRID:AB_2223021
Mouse monoclonal anti-actin, smooth muscle
Clone 1A4
Sigma-Aldrich Cat# A2547; RRID:AB_476701
Rabbit monoclonal anti-Ki67 [SP6] Abcam Cat#ab16667; RRID:AB_302459)
Rabbit polyclonal anti-VCAN Sigma-Aldrich Cat# HPA004726; RRID:AB_1080561)
Rabbit polyclonal anti-COL11A1 Sigma-Aldrich Cat#HPA052246; RRID:N/A
Rabbit polyclonal anti-COL11A1 Novus Cat# NBP2-58159; RRID:N/A
Rabbit polyclonal anti-COL1A1 Abcam Cat# ab21286; RRID:AB_446161)
Rabbit polyclonal anti-FN1 Sigma-Aldrich Cat# F3648; RRID:AB_476976
Rabbit polyclonal anti-CTSB Novus Cat# NBP1-19797; RRID:AB_2086951
Rabbit polyclonal anti-COMP GeneTex Cat# GTX14515; RRID:AB_845475)
Rabbit monoclonal anti-Runx2 [EPR14334] Abcam Cat# ab192256; RRID:AB_2713945
Rabbit monoclonal anti-Vitamin D3Receptor
(D2K6W)
Cell Signaling Technology Cat#12550; RRID:AB_2637002
Rabbit monoclonal anti-Folate Binding Protein
EPR20277
Abcam Cat# ab221543; RRID: N/A
TruStain fcX (anti-mouse CD16/32) Antibody Biolegend Cat#101320; RRID:AB_1574975
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Biological Samples
Human HGSOC omental metastasis samples Barts Health NHS Trust, St. George’s
University Hospitals NHS Foundation
Trust and Barts Gynae Tissue Bank
(https://directory.biobankinguk.org/Profile/
Biobank/GBR-1-128) HTA license number
12199 (REC no: 10/H0304/14 and 15/EE/0151)
Chemicals, Peptides, and Recombinant Proteins
collagenase from Clostridium histolyticum Sigma-Aldrich Cat# C9263
DNase I from bovine pancreas Sigma-Aldrich Cat# D4513
HBSS (10X), no calcium, no magnesium, no
phenol red
GIBCO Cat# 14185-045
Fixable Viability Dye eFluor 506 eBioscience Cat# v65-0866-18
Formalin solution neutral buffered 10% Sigma Aldrich Cat# HT501128
Xylene, Technical, Fisher Chemical Fisher Scientific Cat# X/0100/17
Ethanol, 99.8%, as ethanol,anhydrous,(denat.
with 2% IPA + 2% MEK)
Fisher Scientific Cat#12367103
Hydrogen Peroxide 30-32% (w/w)
(100 Volumes), Certified AR for Analysis
Fisher Scientific Cat# H/1800/15
Methanol 99.9% (GLC) 0.7915 g/mL for
analysis CertiFied AR
Fisher Scientific Cat# M/4000/PB17
Antibody diluent Zytomed Systems Cat# ZUC025-100
Diaminobenzidine substrate-chromogen
(Dako Liquid DAB+ Substrate Chromogen System)
Dako Cat# K3468
Gill’s hematoxylin I Sigma-Aldrich Cat# GHS1128
DPX Mountant for histology Sigma-Aldrich Cat# 06522
Bouin’s Solution Sigma Aldrich Cat# HT10132
Weigert’s Iron Hematoxylin Solution Sigma Aldrich Cat# HT1079
Antigen Retrieval Buffer (100X Tris-EDTA
Buffer, pH 9.0)
Abcam Cat# ab93684
Novocastra protein block Leica Biosystem Cat# RE7102-CE
Bovine Serum Albumin Sigma Aldrich Cat# A4503
Goat serum Sigma Aldrich Cat# G9023
Phosphate-buffered saline (PBS) (1x) GIBCO Cat# 141-90-094
Proteinase K in TE-CaCl2 buffer pH8 Invitrogen Cat# 25530015
Tween 20 Sigma-Aldrich Cat# P7949-500ml
Antigen Unmasking Solution, Citric Acid Based Vector Laboratories Cat# H3300
Triton X-100 Sigma-Aldrich Cat#T8787
Protein Block, Serum-Free DAKO Agilent Cat# X0909
EDTA 0.5M Thermo fisher Cat# AM9262
Doxycycline hyclate Sigma-Aldrich Cat# D9891
DMEM:F12 1:1 with GlutaMax GIBCO Cat# 31331-028
Fetal Bovine Serum Hyclone Cat# 11521831
Penicillin-Streptomycin (10,000 U/mL) Invitrogen Cat# 15140-122
Insulin, Transferrin, Selenium, Sodium
Pyruvate Solution (ITS-A)
Invitrogen Cat# 51300
Hydrocortisone, g-irradiated, powder Sigma Cat# H0135
Murine Epidermal Growth Factor (EGF) Sigma Cat# E4127
Antibiotic-Antimycotic (100X) GIBCO Cat# 5240-062
0.5% Trypsin-EDTA (10X) GIBCO Cat#15400-054
Carboplatin Hospira Cas#41575-94-4
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Fixable Viability Dye eFluor506 eBioscience Cat# 65-0866-14
Collagenase type I Fisher Scientific Cat# 17018-029
Glacial acetic acid Fisher Scientific Cat# 10021123
Critical Commercial Assays
Trichrome Stain (Masson) Kit Sigma-Aldrich Cat# HT15-1KT
anti-rat ImmPRESS-HRP reagent (MP7444, Vector Vector Laboratories Cat# MP7444
ImmPress HRP anti-rabbit (MP7451, Vector) Vector Laboratories Cat# MP7451
Super Sensitive Polymer HRP IHC BioGenex Cat# QD430-XAKE
RNAlater-ice Thermo Fisher Scientific Cat# 4427575
RNeasy Mini kit Quiagen Cat# 74104
RNA NanoChips Agilent Cat# 5067-1511
QiaShredders Quiagen Cat# 79654
RNeasy Plus Mini kit Quiagen Cat# 74134
DNeasy Blood and Tissue kit Quiagen Cat# 69504
Deposited Data
Murine and human omental metastasis data GEO GSE132289
Experimental Models: Cell Lines
60577 Laboratory of Difilippantonio S. Szabova et al., 2014
30200 Laboratory of Difilippantonio S. Szabova et al., 2014
HGS1 This paper N/A
HGS2 This paper N/A
HGS3 This paper N/A
HGS4 This paper N/A
Experimental Models: Organisms/Strains
PAX8-rtTA, TetO-Cre mice Laboratory of Ronny Drapkin Perets et al., 2013
TP53fl/fl [B6.129P2-Trp53tm1Brn/J] mice Jackson Laboratory N/A
PTENfl/fl mice Laboratory of Bart Vanhaesebroeck Groszer et al., 2001
BrCa2fl/fl mice Laboratory of Ashok Venkitaraman Jonkers et al., 2001
FVB mice Charles River N/A
C57/Bl6J mice Charles River N/A
Software and Algorithms
FlowJo software, Tree Star, Inc. FlowJo Software for Mac
Version 10.Ashland
https://www.flowjo.com/solutions/flowjo
NPD.view 2.7.25 software https://www.hamamatsu.com/eu/en/
product/type/U12388-01/index.html
ImageJ 1.48v image processing and analysis
program (NIH, Bethesda, MD) with color
threshold and color deconvolution plug-ins
Schneider et al., 2012;
Ruifrok and Johnston, 2001
https://imagej.nih.gov/ij/ and https://
imagej.net/Colour_Deconvolution
Definiens software (Definiens AG, Germany) http://www.astrazeneca.com
Graphpad Prism, San Diego, CA NA https://www.graphpad.com
R v3.5.1 NA http://www.R-project.org
KCsmart Bioconductor de Ronde et al., 2010
DNACopy Bioconductor Seshan and Olshen, 2019
HTSeq https://htseq.readthedocs.
io/en/release_0.11.1/
Anders et al., 2015
EdgeR Bioconductor Robinson et al., 2010
limma Bioconductor Ritchie et al., 2015
DAVID v6.8 https://david.ncifcrf.gov Huang et al., 2009
Clipper Bioconductor Martini et al., 2013
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GSVA Bioconductor Ha¨nzelmann et al., 2013
siggenes Bioconductor Schwender, 2019
biomaRt Bioconductor Durinck et al., 2009
factoextra CRAN https://cran.r-project.org/web/
packages/factoextra/index.html
dnet CRAN https://cran.r-project.org/web/
packages/dnet/index.html
ggplot2 CRAN https://cran.r-project.org/web/
packages/ggplot2/index.html
WGCNA CRAN Langfelder and Horvath, 2008
classyfire CRAN Chatzimichali and Bessant, 2016
Other
BD LSR Fortessa cytometer BD N/A
Hamamatsu NanoZoomer S210 Slide Scanner N/A N/A
3DHISTECH Panoramic 250 digital slide scanner 3DHISTECH, Hungary N/A
70 mm strainers Fisher Scientific N/A
GentleMACS M Tubes Miltenyi Cat# 130-093-236
Primaria flasks Corning Cat# 353808
Instron ElectroPuls E1000 Instron, UK N/ALEAD CONTACT AND MATERIALS AVAILABILITY
This study did not generate new unique reagents. Further information and requests for resources and reagents should be directed to
and will be fulfilled by the Lead Contact, Frances Balkwill (f.balkwill@qmul.ac.uk).
EXPERIMENTAL MODELS AND SUBJECT DETAILS
Study approval
Murine models
All experimental procedures observed the guidelines approved by the ethics committees of QMUL under the Home Office Project
license PBE3719B3. For survival experiments, mice were culled when they reached humane endpoint as defined in the license.
Patient samples
Samples were kindly donated by HGSOC patients undergoing surgery at Barts Health NHS Trust and St. George’s University
Hospitals NHS Foundation Trust. Tissues deemed by a pathologist to be surplus to diagnostic and therapeutic requirements
were collected along with clinical data under the Barts Gynae Tissue Bank HTA license number 12199 (REC no: 10/H0304/14 and
15/EE/0151). Patients gave written informed consent and the study was approved by a UK national review board. Studies were
conducted in accordance with the Declaration of Helsinki and the International Ethical Guidelines for Biomedical Research Involving
Human Subjects.
Genetic mouse models
Trp53fl/fl mice were acquired from the Jackson Laboratory [B6.129P2-Trp53tm1Brn/J]. Ptenfl/fl mice (Groszer et al., 2001) were a kind
gift from Bart Vanhaesebroeck (UCL Cancer Institute, University College London, UK). Brca2fl/fl mice were a kind gift from Ashok
Venkitaraman (MRC Cancer Unit, University of Cambridge, UK) as originally described in Jonkers et al. (2001). Mice were genotyped
by TransnetYX (Cordova, USA). Trp53fl/fl;Ptenfl/flmice were received fully-backcrossed onto a C57BL/6J background. Brca2fl/flmice
were backcrossed in house for ten generations. When the cell lines were generated, the strain background was checked by SNP
profiling and corresponded to 97% C57BL/6J background. In order to induce the expression of Cre, mice were treated with
0.2mg/ml Doxycycline hyclate (Sigma) in drinking water for 14 days after weaning. All experiments were conducted with femalemice.
Generation and origin of murine cell lines
HGS lines were derived from individual tumors collected in cold PBS, minced with a scalpel, and incubated with 1mg/ml collagenase
type I (Fisher, 17018-029). After being split once onto collagen-coated plates, cells were transferred into Primaria flasks (Corning) and
then propagated as polyclonal lines on normal cell-culture plastic (Corning). Complete medium was DMEM:F12 1:1 with GlutaMaxe4 Cell Reports 30, 525–540.e1–e7, January 14, 2020
(GIBCO) with the addition of 4% FBS (Hyclone), 1x Pen/Strep (Invitrogen), 1x insulin/transferrin/selenium (Invitrogen, 51300),
100 ng/ml hydrocortisone (Sigma, H0135), 20 ng/ml murine Epidermal Growth Factor (EGF, Sigma, E4127), 1x antibiotic-antimycotic
(GIBCO). Cells were trypsinized with 0.05% trypsin-EDTA (GIBCO). 60577 and 30200 cell lines were derived and cultured as
described (Szabova et al., 2014).
Orthotopic tumor growth
Cell lines were trypsinized, washed in medium, and resuspended in PBS to 10x106 cells in 300 ml injected i.p. into 8-week old FVB
mice (60577, 30200) or 6-7-week old C57BL/6J mice (HGS1-4) from Charles River, UK. Mice were treated with 2 mg/kg anti-IL-6 or
isotype control (BioXCell) twice weekly i.p., starting three weeks (60577 model), ten weeks (30200 model) or seven weeks (HGS2
model) after cell injection, until the end of the experiment. Carboplatin (20 mg/kg) was administered i.p. once a week for three weeks
starting at week 3 (60577 model), or week 8 (HGS2 model).
METHOD DETAILS
Array Comparative Genomic Hybridization (aCGH)
Mouse genomic DNA was isolated from frozen tumors, cell lines or mouse tails (for reference controls) using DNeasy Blood and
Tissue kit (QIAGEN). Frozen tissue was processed using TissueLyser II homogenizer at 15 Hz for 40 s prior to DNA extraction.
aCGH was performed using SurePrint G3 mouse CGH 1M microarray kit (Agilent Technologies) or Cancer Research human
CGH+SNP array (Agilent Technologies) as described (Perets et al., 2013). Probe signal intensities were obtained using the feature
extraction software analysis provided by Agilent. Significant recurrent CNA were identified using R package KCsmart (de Ronde
et al., 2010), applying the function findSigLevelTrad with 1000 permutations and a threshold at p < 0.05. To identify CNAs in individual
cell lines and tumors we used the R package DNACopy to generate segmentation data for each sample (Seshan and Olshen, 2019).
Non-redundant copy number regionswere then identified from the segmentation data andmedoids representing a copy number pro-
file for a given genomic region generated using the CNregions function from the R package iClusterPlus.
RNA isolation and sequencing
Total RNA was extracted from frozen murine tumors and non-diseased omenta. The samples were transferred into RNAlater and
homogenized with Miltenyi GentleMACS in RLT buffer and further processed using QIAGEN RNeasy Mini kit with on-column DNase
digestion. RNA integrity numbers (RIN) were above 7.0 with the exception of GEMM tumors which were more degraded. For human
samples total RNAwas extracted from nine omental tumors and three non-involved omental samples. The samples were prepared as
described (Pearce et al., 2018) using QiaShredders and the QIAGEN RNeasy Plus Mini kit with on-column DNase digestion. RNA
quality was analyzed on the Agilent Bioanalyzer 2100 using RNA Nano Chips. RIN numbers were above 7.0. Library preparation
and RNASeq were performed by the Wellcome Trust Centre (Oxford, UK) using RiboZero to deplete rRNA species. Sequencing
was performed to 40x mean depth on the Illumina HiSeq4000 platform, strand-specific, generating 150 bp paired-end reads.
For murine samples, RNASeq reads were mapped to the mouse genome (mm10, Genome Reference Consortium GRCm38) and
for human samples to the human genome (hg19, GenomeReference ConsortiumGRCh37) in strand-specificmode. Number of reads
aligned to the exonic region of each gene were counted using htseq-count (Anders et al., 2015) based on the Ensembl annotation.
Only genes that achieved at least one read count per million reads (cpm) in at least twenty-five percent of the samples were kept.
Conditional quantile normalization (Hansen et al., 2012) was performed accounting for gene length and GC content and a log2-trans-
formed RPKM expression matrix was generated. Four tumor samples and six non-diseased omenta from our prior RNaseq dataset
(GSE71340) were included in the human analysis giving a total of nine tumors and nine non-diseased omenta.
Unsupervised clustering, differential expression and pathways analysis
Principal component and hierarchical cluster analysis were performed on the transformed RPKMmatrix using R package factoextra.
Differential expression analysis was performed in Edge R using limma (Ritchie et al., 2015; Robinson et al., 2010). False discovery rate
(FDR) was calculated using the Benjamini-Hochberg method. Over-representation analysis for GO Biological process, KEGG and
REACTOMEpathways on the common tumor-associated differentially expressed genes inmurinemodels (Figure 1C) was performed
using DAVID v6.8 https://david.ncifcrf.gov. The R package clipper (v3.8) was used to implement topological gene set analysis in
mouse and human omental tumors versus non-diseased omentum (Figure 2C). Heatmaps illustrate concordant orthologous genes
in human and mouse models in commonly enriched gene sets (pathway threshold p < 0.05). Gene Ontology Biological process
enrichment analysis was performed using the R package dnet and dotplot (Figure 2D) was constructed using ggplot2. Single sample
gene-set enrichment analysis (Figure 6A) which calculates a gene-set enrichment score per sample was performed using the R pack-
age GSVA (Ha¨nzelmann et al., 2013). To identify pathways differentially enriched between mouse models we used the function sam
from R package siggenes on the ssGSEA enrichment scores (Schwender, 2019).
Weighted gene co-expression network analysis (WGCNA)
WGCNA (Langfelder and Horvath, 2008) was used to identify correlation patterns among genes on the normalized and transformed
RSEMmatrix of the ICGC OV-AU dataset (Patch et al., 2015). The module eigengene was used as a measure of module expression.Cell Reports 30, 525–540.e1–e7, January 14, 2020 e5
To relate to C1-C5molecular subtypes, gene set GSVA enrichment scoreswere used as sample traits and correlated tomodule eigen
genes. To determine the enrichment of differentially expressed mouse genes in modules generated by WGCNA, mouse identifiers
were first mapped to their corresponding human HGCN Symbol using the R package biomaRt. Module gene enrichment was
then determined using the function userListEnrichment in the WGCNA package and by gene expression/gene module correlations.
Using the ICGC OV-AU set and the TCGA ovarian Affymetrix U133a 2.0 Array (The Cancer Genome Atlas Research Network, 2011)
we also constructed consensusmodules byWGCNA and related module eigen genes to survival, C1-C5molecular subtypes and the
differentially expressed mouse genes as described above.
Multivariate classification of ICGC platinum status using murine model data
The top differentially expressed genes in 60577 versus HGS2 (FDR < 0.0001 and logFC > j3j) with human orthologs sufficiently
detected in ICGCwere obtained, a total of 687 genes. Using the expression of these 687 genesmultivariate classification was applied
on the 80 primary tumor samples of the ICGC data to predict patients’ platinum response status. This was performed using the
R package classyfire (Chatzimichali and Bessant, 2016), which implements ensemble support vector machine (SVM) training and
rigorous performance evaluation. The cfBuild function, designed to produce an ensemble of classifiers (with each classifier being
a collection of multiple individually trained SVMs) was used with bootNum set to 100 and ensNum set to 50. To determine statistical
significance the cfPermute function was used with PermNum set to 100, bootNum 10 and ensNum 20.
Flow cytometry
Mouse tumors were minced and incubated in collagenase from Clostridium histolyticum (Sigma), 2 mg/ml, and DNase I from bovine
pancreas, 25 mg/ml (Sigma) in HBSS (Sigma) for 20-30 min at 37C. The lysate was strained through 70 mm strainers (Fisher Scien-
tific). Cells were counted and 0.5-1x106 cells stained in PBS, 2.5% BSA, 2 mM EDTA after blocking with Trustain (Biolegend) for
15 min. Staining antibodies were diluted 1:200 unless differently specified: anti-CD45-BV785 (1:100, Biolegend), anti-CD3 PE-Cy7
1:50 (Biolegend), anti-CD4 BV605 1:100 (Biolegend), anti-CD8 APC (eBioscience), anti-CD11b BV650 (Biolegend), anti-CD11c
FITC (eBioscience), anti-F4/80 PE (Biolegend), anti-Ly6C eFluor450 (eBioscience, 1:100), anti-Ly6G(Gr1) AF700 (eBioscience),
anti-CD19 PerCP-Cy5.5 (eBioscience), anti-MHCII APC-Cy7 (Biolegend). Viability was assessed with Fixable Viability Dye eFluor506
(eBioscience) diluted 1:500. Staining was performed for 30min at 4C. The cells were finally washed, fixed and analyzed on a BD LSR
Fortessa cytometer. Appropriate Fluorescence Minus One (FMO) controls were used in these experiments. Analysis was performed
with the FlowJo software. Human omental tissue was processed and stained similarly as previously described (Bo¨hm et al., 2016).
Histopathology, immunohistochemistry and morphometry
Omental tumors were dissected, fixed in 4% formaldehyde for 24 hr, paraffin-embedded and sectioned (4 mm), followed by H&E
staining. Formalin-fixed paraffin-embedded sections (4 mm) of omental samples were heated for 1hr at 60C and then submerged
twice in xylene for 5min. Slides were then gradually re-hydrated by submerging for 2min in each of the following ethanol solutions:
100%, 90%, 70%, 50% and finally in ddH2O for 3min. Antigen retrieval was performed for all stainings apart from alpha-SMA, FN1
and COMP. The slides were subsequently washed, treated with 3%H2O2 (Fisher Scientific, H/1800/15) in PBS, methanol or water for
5-10min, washed again and blocked with blocking buffer for 20min-1hr. The primary antibody was added in in blocking buffer and
incubated at ambient temperature (Table S7). Slides were washed 3 times and the primary antibody was detected as described in
Table S7. Color was developed with Diaminobenzidine substrate-chromogen (Dako Liquid DAB+ Substrate Chromogen System,
K3468 Dako) and tissues were counterstained with Gill’s hematoxylin I (Sigma-Aldrich, GHS1128), washed, dehydrated in ethanol
and mounted in DPX (Sigma-Aldrich, 06522).
Masson’s trichrome
For Masson’s trichrome staining of omental samples, the Trichrome Stain (Masson) Kit (HT15-1KT) from Sigma was used. Briefly,
formalin-fixed paraffin-embedded 4-mm sections were submerged twice in xylene for 5min and gradually re-hydrated by submerging
for 2min in each of the following ethanol solutions: 100% (X2), 90%, 70%, and finally 50%. Slides were further hydrated for 3min in
ddH2O and fixed in preheated Bouin’s for one hour at 60C. Upon fixation, sections were washed in running water until the yellow
color disappeared, rinsed in two changes of distilled water and stained in working Weigert’s Iron Hematoxylin Solution for 5 minutes
(Sigma, HT1079-1SET). Subsequently, sections were washed in running tap water for 2 minutes, rinsed in ddH2O and stained in
Biebrich Scarlet-Acid Fucshin for 15 minutes. Sections were then rinsed in ddH2O and immersed inWorking Phosphotungstic/Phos-
phomolybdic Acid solution for 10-15 minutes, until collagen fibers were not red. Next, Aniline Blue Solution was applied for 30 mi-
nutes; sections were rinsed in ddH2O and placed in 1% acetic acid for 3 minutes. Finally, sections were dehydrated very quickly
in two changes of 90% alcohol, followed by 2 changes of absolute alcohol, cleared in xylene and mounted.
Generation of tissue-matrix heatmaps
Serial sections of the HGSmouse tumors, along with normal omenta were stained by immunohistochemistry for all 6 ECMmolecules
and scanned with Hamamatsu NanoZoomer S210 Slide Scanner. Digital images from the serial sections were obtained using the
NPD.view 2.7.25 software under the same magnification. The ImageJ (ImageJ 1.48v) image processing and analysis program
(NIH, Bethesda, MD) with color threshold and color deconvolution plug-ins was used for the generation of tissue matrisomee6 Cell Reports 30, 525–540.e1–e7, January 14, 2020
heatmaps. Briefly, images were aligned and color deconvoluted and all six isolated DAB images were subsequently converted to
single color images and compiled to a Z stack (AVG stack), selecting average intensity. A tissue matrix heatmap was generated
by applying an edited Royal filter to the AVG stack, so that each color corresponds to either the absence (black) or the presence
in situ of one (dark blue), two (cyan), three (green), four (yellow), five (orange) or six (red) ECM molecules. Finally, a Calibration bar
was applied to the AVG stack with all seven colors and the heatmap image was flattened before export.
Mechanical characterization
Mechanical characterization was performed on frozen murine or human tissues using a flat-punch indentation methodology on an
Instron ElectroPuls E1000 (Instron, UK) equipped with a 10 N load cell (resolution = 0.1 mN) as described (Delaine-Smith et al.,
2016; Pearce et al., 2018).
QUANTIFICATION AND STATISTICAL ANALYSIS
Tissue sections were scanned either using a 3DHISTECH Panoramic 250 digital slide scanner (3DHISTECH, Hungary) or with
Hamamatsu NanoZoomer S210 Slide-Scanner and the scans analyzed using Definiens software (Definiens AG, Germany).
Bioinformatic analyses were performed in the statistical programming language R (version 3.5.1). All other statistical analyses
were performed using Graphpad Prism, San Diego, CA. Statistical tests used, n numbers and P values are displayed in the appro-
priate figures and figure legends. P values < 0.05 were considered statistically significant.
DATA AND CODE AVAILABILITY
The accession number for the RNASeq data reported in this paper is Gene Expression Omnibus (GEO): GSE132289. R markdown
scripts enabling the main steps of the analysis are available from the Lead Contact upon reasonable request.Cell Reports 30, 525–540.e1–e7, January 14, 2020 e7
